Impact of mycophenolate mofetil on wound complications and lymphoceles after kidney transplantation

Kidney and Blood Pressure Research

Volumn 33, Issue 1, 2010, Pages 52-59

  Lopau, Kai ^a   Syamken, Karin ^a   Rubenwolf, Peter ^a   Riedmiller, Hubertus ^a   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immunosuppression; Kidney transplantation; Lymphoceles; Mycophenolate mofetil; Wound healing

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERVENTION STUDY; KIDNEY TRANSPLANTATION; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCLEROTHERAPY; WOUND COMPLICATION; WOUND HEALING;

ADULT; AGED; AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; RETROSPECTIVE STUDIES; RISK FACTORS; WOUND HEALING;

EID: 77449129081     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000289573     Document Type: Article

References (22)

1. Oniscu GC, Brown, H, Forsythe JLR: Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005; 16: 1859-1865.
2. Mehrabi A, Fonouni H, Wente M, et al: Wound complications following kidney and liver transplantation. Clin Transplant 2006; 20(suppl 17):97-110.
3. Hernández D, Rufino M, Armas S, et al: Retrospective analysis of surgical complications following cadaveric kidney transplantation in the modern transplant era. Nephrol Dial Transplant 2006; 21: 2908-2915.
4. Ghasemian SMR, Guleria AS, Khawand NY, Light J: Diagnosis and management of the urologic complications of renal transplantation. Clin Transplant 1996; 10: 218-223.
5. van Roijen JH, Kirkels WJ, Zietse R, Roodnat JI, Weimar W, Ijzermans JN: Long-term graft survival after urological complications of 695 kidney transplantations. J Urology 2001; 165: 1884-1887.
6. Cohan RH, Saeed M, Sussman SK, et al: Percutaneous drainage of pelvic lymphatic fluid collections in the renal transplant patient. Invest Radiol 1987; 22: 864-867.
7. Humar A, Ramcharan T, Denny R, Gillingham KJ, Payne WD, Matas AJ: Are wound complications after a kidney transplant more common with modern immunosuppression? Transplant 2001; 72: 1920-1923.
8. Johnson CP, Kuhn EM, Hariharan S, et al: Pre-transplant identification of risk factors that adversely affect length of stay and charges for renal transplantation. Clin Transplant 1999; 13: 168-175.
9. Langer RM, Kahan BD: Incidence, therapy, and consequences of lymphocele after sirolimus- cyclosporine-prednisone immunosuppression in renal transplant patients. Transplant 2002; 74: 804-808.
10. Khauli RB, Stoff JS, Lovewell T, et al: Post transplant lymphoceles: a critical look into the risk factors pathophysiology and management. J Urol 1993; 150: 22-26.
11. Stephan RN, Munschauer CE, Kumar MS: Surgical wound infection in renal transplantation: outcome data in 102 consecutive patients without perioperative systemic antibiotic coverage. Arch Surg 1997; 132: 1315-1318.
12. Halloran P, Mathew T, Tomlanovich S, et al: Mycophenolate mofetil in renal allograft recipients: a pooled efficiency analysis of three randomized, double-blind, clinical trials in preventing rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplant 1997; 63: 39-47.
13. Ojo AO, Meier-Kriesche HU, Hanson JA, et al: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplant 2000; 69: 2405-2409.
14. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al: Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplant 2003; 75: 1341-1346.
15. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanism of action. Immunopharmacology 2000; 47: 85-118.
16. Carr SF, Papp E, Wu JC, Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-27290.
17. Badid C, Vincent M, McGregor B, et al: Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in the rat remnant kidney. Kidney Int 2000; 58: 51-61.
18. Heinz C, Hudde T, Heise K, Steuhl KP: Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts. Graefes Arch Clin Exp Ophtalmol 2002; 240: 408-414.
19. Morath C, Zeier M: Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Pharmacol Ther 2003; 41: 465-469.
20. Knight RJ, Villa M, Laskey R, et al: Risk factors for impaired wound healing in irolimustreated renal transplant recipients. Clin Transplant 2007; 21: 460-465.
21. Morath C, Reuter H, Simon V, et al: Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivo. Am J Transplant 2008; 8: 1786-1797.
22. Kuppahally S, Al-Khaldi A, Weisshaar D, et al: Wound healing complications with de novo irolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6: 986-992.